Evogene shares rise 14.94% after-hours after appointing Dr. Olga Nissan as VP of Business Development.
ByAinvest
Wednesday, Dec 31, 2025 4:45 pm ET1min read
EVGN--
Evogene surged 14.94% in after-hours trading following the announcement of Dr. Olga Nissan's appointment as Vice President of Business Development. Dr. Nissan, a biotechnology and pharmaceutical executive with over 15 years of experience in R&D, clinical development, and business operations, brings expertise from roles at Protica Bio, EcoPhage, BiomX, and Teva. The company emphasized her strategic leadership in scaling Evogene’s AI-driven small-molecule drug discovery platform, ChemPass, and expanding partnerships. CEO Ofer Haviv highlighted her role in accelerating "Real-World Innovation" through industry collaborations. The hiring is seen as a catalyst for growth in pharmaceutical and agricultural markets, aligning with the stock’s sharp post-announcement rally.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet